Abstract:MicroRNAs (miRNAs) are the most abundant RNA species found in serum, and recently, several miRNAs have been found to be associated with osteoporosis. However, the development of such associated miRNAs into diagnostic and therapeutic targets remains unaddressed, mostly because of a lack of functional validation. Here, we identified circulating miR-338 associated with postmenopausal osteoporosis, and performed functional validation in vivo and in vitro.Methods: We collected the serum from postmenopausal osteoporosis patients (N=15) and female volunteers of the same age but with normal bone density (N=15) and examined the enrichment of miR-338 cluster. We also confirmed such enrichment using mice subjected to ovariectomy at different stages. We employed primary bone marrow stromal cells from mice and the MC-3T3 cell line along with CRISPR, RNA-seq and ChIP-qPCR to validate the biological function of secreted miR-338 cluster on osteoblastic differentiation and their upstream regulators. Moreover, we generated miR-338 knockout mice and OVX mice injected with an inhibitor against miR-338 cluster to confirm its biological function in vivo.Results: We observed a significant enrichment of miR-338 cluster in postmenopausal osteoporosis patients. Such enrichment was also prominent in serum from mice subjected to ovariectomy and was detected much earlier than bone density decreases revealed by micro-CT. We also confirmed the presence of an estrogen-dependent Runx2/Sox4/miR-338 positive feedback loop that modulated osteoblast differentiation, providing a possible explanation for our clinical findings. Moreover, deletion of the miR-338 cluster or direct intravenous injection of an miR-338 cluster inhibitor significantly prevented osteoporosis after ovariectomy.Conclusion: Circulating miR-338 cluster in the serum could serve as a promising diagnostic and therapeutic target for postmenopausal osteoporosis patients.

MiR-206 regulates the progression of osteoporosis via targeting HDAC4

Identification of Suitable Reference Gene and Biomarkers of Serum Mirnas for Osteoporosis

Mir-664-3p Suppresses Osteoblast Differentiation And Impairs Bone Formation Via Targeting Smad4 And Osterix

A Comprehensive Analysis of MicroRNAs in Human Osteoporosis

Reduced Mir-144-3p Expression in Serum and Bone Mediates Osteoporosis Pathogenesis by Targeting RANK.

Identification of Differentially Expressed Micrornas in the Bone Marrow of Osteoporosis Patients.

MicroRNA-410 Participates in the Pathological Process of Postmenopausal Osteoporosis by Downregulating Bone Morphogenetic Protein-2

Mir-214 Targets Atf4 to Inhibit Bone Formation

Mir-140-3p Aggregates Osteoporosis by Targeting PTEN and Activating PTEN/PI3K/AKT Signaling Pathway.

Synergistic effects of miR-708-5p and miR-708-3p accelerate the progression of osteoporosis

LncRNA AC003090.1 Mediates miR-203a-3p/FOXP1 Axis to Promote the Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells

Circulating Mir-181C-5p and Mir-497-5p Are Potential Biomarkers for Prognosis and Diagnosis of Osteoporosis

Biological Role of miRNA-302a-3p/DKK1 in Osteogenesis of Bone-Marrow Derived Mesenchymal Stem Cells

Circulating miR-338 Cluster activities on osteoblast differentiation: Potential Diagnostic and Therapeutic Targets for Postmenopausal Osteoporosis

Mir-Oz Kegulates Osteoblast Apoptosis, Proliferation and Differentiation Through Targeted Inhibition of Runx2 in Osteoporosis Running Title: Role and Potential Mechanism of Mir-152 in Osteoporosis

MiR-503 Regulates Osteoclastogenesis Via Targeting RANK

MicroRNA-532-5p is implicated in the regulation of osteoporosis by forkhead box O1 and osteoblast differentiation

MicroRNA-497-5p stimulates osteoblast differentiation through HMGA2-mediated JNK signaling pathway

Osteoclast-derived Exosomal Mir-214-3p Inhibits Osteoblastic Bone Formation.

miR-34a-5p facilitates osteogenic differentiation of bone marrow mesenchymal stem cells and modulates bone metabolism by targeting HDAC1 and promoting ER-α transcription

Overexpression of miR-195-5p reduces osteoporosis through activating BMP-2/SMAD/Akt/RUNX2 pathway via targeting SMURF1.